Vital Signs buys fluid warming company:
This article was originally published in Clinica
Executive Summary
Anaesthesia breathing systems manufacturer Vital Signs has bought blood warming technology specialist Enginivity in a deal worth $5.9m. The deal sees Totowa, New Jersey-based Vital Signs acquire the enFlow device, a fluid warming system that brings the warming element closer to the patient, reducing heat loss and post-operative infections. The enFlow device will be introduced to market in November, and provides the company with an entry into what it claims is a $40-45m domestic market. Enginivity (Lexington, Massachusetts) sold its FDA-cleared and CE-marked products to hospitals and the US government but received no revenue in 2006.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.